The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population, together with additional emerging agents with novel MOAs and a general increase in the use of biologics to maintain disease control, will help drive market growth. In contrast to these factors, the expected generic entry of leading branded conventional agents (e.g., Shire’s Lialda), continuing generic erosion of other conventional agents, and the additional entries and expanded use of less-expensive biosimilar TNF-alpha inhibitors (e.g., Pfizer’s Inflectra, Amgen’s Amjevita) will constrain the UC market. Indeed, given the increasing competition in the UC market—for both branded and generic/biosimilar agents—emerging therapies looking to penetrate this market will need to be clearly differentiated from competitors.
QUESTIONS ANSWERED
What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?
What will be the impact of the anticipated entry of generics for the remaining key branded conventional agents (e.g., Lialda, Valeant’s Apriso)?
How do physicians currently perceive biosimilar agents, and what impact are these agents expected to have on the UC market?
What do KOLs think about key emerging therapies (e.g., Pfizer’s Xeljanz, Roche/Genentech’s etrolizumab, and Celgene’s ozanimod), and where do they see these agents fitting into the treatment algorithm?
PRODUCT DESCRIPTION
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.